实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床观察

张林曦; 冯卓; 杨巍

doi:10.16305/j.1007-1334.2021.1904093

您当前的位置：

首页 >

文章列表页 >

实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床观察

临床试验 | 更新时间：2022-08-02

- 实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床观察
- Clinical observation on Shiyan Prescription in treating mild and moderate ulcerative colitis of large intestine damp-heat syndrome
- 上海中医药杂志 2021年55卷第1期页码：43-46
- 作者机构：
  
  1.上海中医药大学附属曙光医院（上海　201203）
- 作者简介：
  
  张林曦，女，硕士研究生，主要从事消化内镜及中西医结合治疗消化系统疾病的临床研究工作
  杨巍, 主任医师，博士研究生导师；E-mail:yangweiyishi@163.com
- 基金信息：
  
  上海市卫计委“十三五”上海市临床重点专科建设项目(shslczdzk04302)
- DOI：10.16305/j.1007-1334.2021.1904093
  中图分类号：
扫描看全文
张林曦, 冯卓, 杨巍. 实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床观察[J]. 上海中医药杂志, 2021,55(1):43-46.

Linxi ZHANG, Zhuo FENG, Wei YANG. Clinical observation on Shiyan Prescription in treating mild and moderate ulcerative colitis of large intestine damp-heat syndrome[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(1):43-46.
张林曦, 冯卓, 杨巍. 实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床观察[J]. 上海中医药杂志, 2021,55(1):43-46. DOI： 10.16305/j.1007-1334.2021.1904093.

Linxi ZHANG, Zhuo FENG, Wei YANG. Clinical observation on Shiyan Prescription in treating mild and moderate ulcerative colitis of large intestine damp-heat syndrome[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(1):43-46. DOI： 10.16305/j.1007-1334.2021.1904093.

摘要

目的,2,观察实炎方治疗轻中度大肠湿热型溃疡性结肠炎的临床疗效。,方法,2,将60例大肠湿热型溃疡性结肠炎患者随机分为治疗组和对照组，每组30例。治疗组予以中药实炎方口服，对照组予以美沙拉嗪肠溶片口服。两组疗程均为3个月，观察临床疗效，比较主要症状量化积分、修正的Baron评分及血清中白介素-1β（IL-1β）、白介素-10（IL-10）水平的变化情况。,结果,2,①治疗组、对照组总有效率分别为93.33%、86.67%；组间临床疗效比较，治疗组明显优于对照组（,P,<,0.05）。②治疗前后组内比较，两组主要症状量化积分均下降，差异有统计学意义（,P,<,0.05）；组间积分下降差值比较，治疗组明显高于对照组（,P,<,0.05）。③治疗前后组内比较，两组修正的Baron评分均下降（,P,<,0.05）；组间评分下降差值比较，治疗组明显高于对照组（,P,<,0.05）。④治疗前后组内比较，两组IL-1β水平均明显降低，IL-10水平均明显升高（,P,<,0.05）；组间治疗后比较，治疗组IL-1β水平明显低于对照组，IL-10水平明显高于对照组（,P,<,0.05）。,结论,2,相比美沙拉嗪，实炎方能更好地改善溃疡性结肠炎患者的主要临床症状及结肠黏膜病变，降低血清IL-1β水平，提高血清IL-10水平。

Abstract

Objective,2,To observe the clinical effect of Shiyan Prescription on mild and moderate ulcerative colitis (UC) of large intestine damp-heat syndrome.,Methods,2,Sixty patients with ulcerative colitis of large intestine damp-heat syndrome were randomly divided into treatment group and control group, with 30 cases in each group. The treatment group was administered Shiyan Prescription orally, while the control group was administered mesalazine enteric coated tablets orally. The course of treatment in both groups was 3 months. The clinical efficacy was observed, and the quantitative score of main symptoms, modified Baron score and the level changes of serum cytokines interleukin-1β (IL-1β) and interleukin-10 (IL-10) levels were detected and compared before and after treatment.,Results,2,①The total effective rates of the treatment group and the control group were 93.33% and 86.67% respectively. The clinical efficacy of the treatment group was significantly better than that of the control group (,P,<,0.05). ②The quantitative scores of main symptoms in the two groups both decreased after treatment, and the difference before and after treatment was statistically significant (,P,<,0.05). The treatment group showed more significant difference of main symptoms quantitative scores than that of the control group (,P,<,0.05). ③The modified Baron score in the two groups both decreased after treatment(,P,<,0.05). The treatment group showed more significant difference of modified Baron score than that of the control group (,P,<,0.05). ④The expression level of IL-1β decreased significantly and the expression level of IL-10 increased significantly in both groups after treatment (,P,<,0.05). The treatment group showed lower expression level of IL-1β and higher expression level of IL-10 compared with the condition in the control group after treatment (,P,<,0.05).,Conclusion,2,Compared with mesalazine, Shiyan Prescription can better improve the main clinical symptoms and colonic mucosal lesions, reduce the level of serum IL-1β and increase the level of serum IL-10 in patients with ulcerative colitis.

关键词

溃疡性结肠炎实炎方美沙拉嗪大肠湿热证中药抗炎结肠黏膜病变

Keywords

ulcerative colitisShiyan Prescriptionmesalazinelarge intestine damp-heat syndromeTCM anti-inflammationcolonic mucosal lesion

references

李军祥，谭祥，毛堂友.溃疡性结肠炎中西医结合治疗策略[J].中国中西医结合杂志，2017,37(4):398-400.

PODOLSKYD K.Inflammatory bowel disease[J].N Engl J Med，2002(347):417-429.

王俊珊，刘占举.炎症性肠病的诊断和药物治疗相关指南解读[J].世界临床药物，2015,36(12):809-813.

向未，刘菊容，杨伟兴.参苓白术免煎颗粒剂联合乐托尔、美沙拉嗪治疗溃疡性结肠炎的临床观察[J].中医临床研究，2017,9(25):42-44.

DELTENRE P，BERSON A，MARCELLIN P，et al.Mesalazine（5-aminosalicylic acid）induced chronic hepatitis[J].Gut，1999,44(6):886-888.

徐浩，张巍，仇菲，等.杨巍治疗炎症性肠病经验[J].上海中医药杂志，2018,52(4):29-31.

中华医学会消化病学会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2018年，北京）[J].中国实用内科杂志，2018,38(1):796-808.

中华中医药学会.中医内科常见病诊疗指南·西医疾病部分[M].北京：中国中医药出版社，2008:107-110.

中华医学会.临床诊疗指南·消化系统疾病分册[M].北京：人民卫生出版社，2005:45-47.

欧阳钦，苗新普.炎症性肠病评估指标的临床应用[J].中华消化杂志，2009,29(3):209-212.

DANIEL W W.Sample size calculator.[2019-03-15].https://goodcalculators.com/sample-size-calculator/https://goodcalculators.com/sample-size-calculator/.

中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗指南（草案）[J].中国中西医结合消化杂志，2011,19(1):61-65.

BARON J H，CONNELL A M，LENNARD J E.Variation between observers in describing mucosal appearances in proctocolitis[J].Br Med J，1964(1):89-92.

ANGY S，MAHMUD N，WHITE B，et al.Randornized comparison of unfractionated heparin in with cortieosteroids in servere active inflammatory bowel disease[J].Aliment Pharmacol Ther，2000,14(8):1015-1022.

SEHGAL P，COLOMBEL F，ABOUBAKR A，et al.Systematic review：safety of mesalazine in ulcerative colitis[J].Aliment Pharmacol Therap，2018,47(12):1597-1609.

肖建兵，赖晓霖.中西医结合治疗溃疡性结肠炎[J].实用中西医结合临床，2011,11(6):56-57.

姚钦恩.中西医结合治疗溃疡性结肠炎疗效评价[J].现代诊断与治疗，2012,23(4):228-229.

陈治水，危北海，张万岱，等.溃疡性结肠炎中西医结合诊治方案（草案）[J].中国中西医结合消化杂志，2005,13(2):133-137.

BAUMGART D C，THOMAS S，PRZESDZING I，et al.Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease[J].Clin Exp Immunol，2009,157(3):423-436.

HOENTJEN F，HARMSEN H J，BRAAT H，et al.Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice[J].Gut，2003(52):1721-1727.

张晓博，杨宪武，党惠娇，等.溃疡性结肠炎患者血清和结肠组织白细胞介素8和白细胞介素10的表达[J].临床荟萃，2010,25(3):210-212.

贾百灵，侯晓华.溃疡性结肠炎患者血清白细胞介素1β检测[J].郑州大学学报（医学版），2004,39(2):306-308.

李乃谦.探讨白芍的药理作用及现代研究进展[J].中医临床研究，2017,9(20):137-138.

周进.白芍总苷对实验性结肠炎的影响及机制[D].合肥：安徽医科大学，2009.

王佐，吴正祥，杨九华，等.白芍总甙对大鼠实验性结肠炎Th17细胞相关因子的作用[J].世界华人消化杂志，2010,18(1):84-88.

夏渝林.马齿苋抗菌作用的初步分析[J].时珍国医国药，2007,18(5):1153.

鄢伟伦，王帅帅，任霞.白术对小鼠肠道菌群调节作用的实验研究[J].山东中医杂志，2011,30(6):417-419.

颜正华.颜正华中药学讲稿[M].北京：人民卫生出版社，2011.

侯安继，项荣，彭施萍.茯苓多糖抗炎作用的研究[J].中药药理与临床，2003,19(3):15-16.

HARUO N，HIROTATSU F，HIROKAZU Y，et al.Isolation of inhibitor of TPA-induced mouse ear edema from hoelen，poria cocos[J].Chem Pharm Bull，1996,44(4):847-849.

陈阳峰，钟晓红.黄柏的药理作用及其活性成分提取[J].作物研究，2015,29(5):564-568.

李仲兴，赵建宏，王秀华，等.用新方法进行黄柏对224株葡萄球菌的体外抗菌活性研究[J].中医药信息，2000,17(5):33-35.

王跃华，徐文俊，何俊蓉，等.川黄柏离体培养及药用成分的抑菌试验研究[J].中国中药杂志，2004,29(10):1002-1004.

UEDE H，YAMAZAKI M.Inhibition of tumor necrosis factor-α production by orally administering a perilla leaf extracts[J].Biosci Biotech Biochem，1997,61(8):1292-1295.

马少波.黄连的药理作用及临床新用[J].中国民间疗法，2013,21(6):58-59.

王锦，石晓霞，刘翠青.中药木香乙醚部分提取物抗串珠镰孢菌作用研究[J].河北中医药学报，2006,21(1):21-22.

浏览量

254

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

白头翁汤加减联合美沙拉嗪治疗溃疡性结肠炎的Meta分析

丹参注射液联合美沙拉嗪对轻中度活动期溃疡性结肠炎患者血清HIF-1α、炎症细胞因子水平的影响

胆汁酸代谢及其受体调节溃疡性结肠炎肠道免疫及中药干预研究进展

复方苦参汤对溃疡性结肠炎小鼠结肠组织中炎症因子及自噬水平的影响

基于图像数据化的溃疡性结肠炎患者舌象与肠镜象的关系研究